Merz Celebrates a Monumental Milestone: One Million Treatments Worldwide with Ultherapy®
Merz Aesthetics, a division of Merz Pharma Group, announced today that Ultherapy ® is celebrating the milestone achievement of conducting one million treatments globally. Since its global launch in 2008 and U.S. launch in 2009, the non-invasive ultrasound device has become a game-changer in physician offices worldwide for lifting and tightening skin with its cutting-edge technology. The revolutionary treatment is currently the first and only treatment FDA-cleared to non-invasively lift the eyebrow, neck, and chin, and to improve lines and wrinkles on the décolletage via micro-focused ultrasound. Ultherapy ® also conforms to the European level of quality and safety for medical devices.
“It is no surprise that Ultherapy® has reached one million treatments worldwide - it is a favorite treatment that I recommend to patients requesting skin lifting and tightening,” stated Dr. Doris Day, board certified dermatologist and founder of Day Dermatology and Aesthetics. “The technology not only naturally stimulates collagen growth and provides visible results, but also little to no downtime post treatment.”
Making the treatment even more popular amongst physicians, Ultherapy® is the only cosmetic procedure to use ultrasound imaging, which allows physicians to see the layers of tissue targeted during the treatment to ensure the energy is deposited where it will be most beneficial. This unique technology is supported by more than 50 clinical studies, more than 60 published, peer-reviewed papers, and over 100 patents.
“We’re extremely proud to be celebrating this milestone of treating one million patients with Ultherapy® on a global scale,” said Philip Burchard, Chief Executive Officer, Merz Pharma. “Ultherapy® continues to lead in the category due to its breakthrough, award-winning innovation, our dedicated physicians, and consistent patient satisfaction. We look forward to celebrating the next million treatments.”
For more information on Ultherapy® , please visit www.global.ultherapy.com .
For more information on Merz Pharma Group, please click on www.merz.com .
Mariana Smith Bourland
Phone: +49 151 4249 1466
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Business Wire
CT-PROTON-ONSITE23.10.2017 23:04 | pressemeddelelse
Proton OnSite Has Been Awarded a Contract for Approximately USD 1.8 Million and Assumes the Lead Role in the US Government Advanced Water Splitting Benchmarking Project
SES23.10.2017 19:16 | pressemeddelelse
SES Networks Works with Project Loon to Restore Connectivity in Puerto Rico
SAGEMCOM23.10.2017 18:07 | pressemeddelelse
Sagemcom Unveils the Next-Generation Multi-Gigabit Solutions
PA-KNOPP-BIOSCIENCES-LLC23.10.2017 17:13 | pressemeddelelse
Knopp Biosciences Announces Renewal of NIH Blueprint Grant Award for Advancing KCNQ2 Modulators in Epilepsy
NY-MOODY'S-ANALYTICS23.10.2017 16:02 | pressemeddelelse
Moody’s Analytics Launches the CreditLens™ Platform
HCL-TECHNOLOGIES23.10.2017 15:04 | pressemeddelelse
HCL Technologies Powers Volvo Ocean Race 2017-18
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum